Pharmacare Premium Claims Pole Position On Pazopanib
Malta-Based Generics Developer Reports Two Successful Bioequivalence Trials
Malta-based generics developer and manufacturer Pharmacare Premium believes it is leading the way on developing a generic pazopanib rival to Novartis’ Votrient cancer treatment for the European market.
You may also be interested in...
Hyloris is on a roll with licensing deals for its Maxigesic IV non-opioid pain treatment, with an extension of its existing agreement with Pharma Bavaria to cover South American territories coming hot on the heels of recent developments in the US and Europe.
Australia’s government has agreed to extend a successful biosimilar education initiative led by the local GBMA industry association.
Despite turnover dropping by over a fifth in its financial third quarter, Lannett says it is optimistic that respiratory generics and insulins will offer the firm “durable” opportunities in future. The company has also just reorganized its finances to extend its debt maturity by four years, pushing it back past some of its key launches.